ABSI

$2.96-0.12 (-3.90%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.96
Potential Upside
5%
Whystock Fair Value$3.11
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$445.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.13
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-54.49%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
5.89

Recent News

MarketBeat
Mar 22, 2026

Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028

Recursion Pharmaceuticals (NASDAQ:RXRX) Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery and development, recent portfolio decisions, partnership economics, and cash runway during a fireside chat hosted by KeyBank healthcare tech equity analy

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Zacks
Mar 19, 2026

InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates

InflaRx (IFRX) delivered earnings and revenue surprises of +2.86% and -117.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
MarketBeat
Mar 9, 2026

Absci Highlights AI Antibody Platform, ABS-201 Hair-Loss Trial Milestones at Leerink Conference

Absci (NASDAQ:ABSI) used a presentation at the Leerink Partners Global Healthcare Conference to outline how the company is applying its internal AI-driven drug design platform to generate “differentiated” antibody assets, while advancing its own lead clinical program, ABS-201, in androgenetic alopec

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 2, 2026

Absci Conference: Agentic AI Push and ABS-201 Hair-Loss Program Take Center Stage

Executives from Absci (NASDAQ:ABSI) used a conference presentation to emphasize the company’s focus on building clinical-stage drug assets using artificial intelligence, with management repeatedly framing long-term value creation around programs that advance into and through the clinic rather than s

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jan 21, 2026

Absci Corporation's (NASDAQ:ABSI) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures

Key Insights Significantly high institutional ownership implies Absci's stock price is sensitive to their trading...

BEARISH
Negative press. News cycle fixated on risk factors or misses.